v3.26.1
INCOME TAXES (Tables)
12 Months Ended
Apr. 30, 2026
Income Tax Disclosure [Abstract]  
Schedule of net pre-tax book income and/or loss
          
   Years Ended April 30, 
   2026   2025 
United States  $(19,424,654)  $30,656,050 
Foreign        
Total  $(19,424,654)  $30,656,050 

Schedule of effective income tax rate
          
   Year Ended April 30, 2026 
U.S. federal statutory tax rate  $(4,079,177)   21.0% 
State income taxes, net of federal income tax effect (1)       
Foreign tax effects        
Changes in valuation allowances   2,998,757    (15.4)
Non-taxable or non-deductible items          
Fair value of warranty liability   996,688    (5.1)
Gain on related party investment - QCLS   (438,690)   2.3 
Fair value of derivative liability   (234,570)   1.2 
Issuance costs on Series C convertible preferred stock and warrants   259,256    (1.3)
Other   (27,287)   0.1 
Other adjustments          
Expired warrant assets   963,271   (5.0)
Redemption of note receivable   (700,140)   3.6 
Forgone benefit on federal tax NOLs   369,981    (1.9)
Other   (108,089)   0.5 
Effective tax rate  $    % 
Schedule of provision for income taxes
     
  

Year Ended

April 30, 2025

 
Federal benefit at statutory rate  $6,437,771 
State income taxes, net of Federal taxes   2,139,792 
Fair value of warrant liability   (2,922,791)
Gain on related party investment   (5,986,526)
Fair value of derivative liability   (611,083)
Redemption of derivative liability   (174,862)
Expiration of warrant asset – Series B   (79,743)
State deferred tax adjustment   572,607 
Legal settlement   131,226 
Provision related to change in valuation allowance   27,998 
Fair value of warrant asset – Series B   385,005 
Expired stock options   78,384 
Net valuation allowance for state NOLs   (6,748)
Other, net   8,970 
Effective tax rate  $ 
Schedule of deferred tax assets and liabilities
          
   April 30, 
   2026   2025 
Deferred tax assets:          
Net operating loss carryforwards  $16,079,880   $15,026,112 
Stock compensation   569,229    523,822 
Research and development   63,232    216,831 
Investment in SG Austria   439,953    439,953 
Intangible asset (diabetes license)   559,672    559,672 
Intangible asset (value of cells)   433,585     
Fair value of investment in QCLS   511,464     
Fair value of warrant asset   

493,351

     
Other - deferred tax asset   217,244    147,798 
Total deferred tax assets   19,367,610    16,914,188 
           
Deferred tax liabilities:          
Fair value of convertible note receivable       (568,067)
Fair value of warrant asset       (228,906)
Fair value of investment in QCLS       (754,512)
Other - deferred tax liability       (140,985)
Total deferred tax liabilities       (1,692,470)
           
Total deferred tax assets   19,367,610    15,221,718 
Valuation allowance   (19,367,610)   (15,221,718)
Net deferred tax assets  $   $